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Cytomegalovirus (CMV) drug resistance mutations, because of the 
widespread use of ganciclovir, have been widely reported in international 
literature, particularly in the post-transplant setting. However, a genotypic 
assay to detect CMV drug resistance is not available in South Africa and the 
prevalence of these mutations is therefore unknown. 
 
We aimed to document the prevalence and types of CMV UL97 mutations 
following exposure to ganciclovir in adult and paediatric oncology patients, 
transplant recipients and HIV-infected patients in the local tertiary level 
hospitals: Red Cross War Memorial Children’s Hospital, Groote Schuur 




The study had two components, the first component being a retrospective 
cross-sectional study using stored extracted DNA from patients with serially 
elevated CMV viral load levels. Thirty-three samples were tested for this 
component. 
 
The second component was a prospective case series on patients who were 
referred by clinicians for genotypic testing in whom CMV drug resistance was 
suspected. Eight samples were tested for this component. The CMV UL97 
gene was amplified by conventional nested polymerase chain reaction (PCR) 




CMV UL97 mutations were identified in five of thirty-three (15%) 
retrospectively screened samples while the prospective testing of eight 
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patient samples identified drug resistance mutations in three patients (38%). 
Overall 8/41 (20%) patients had CMV UL97 mutations. A trend of higher risk 
for development of drug resistance mutations among haematological 
oncology patients 7/23 (30%) compared to solid organ transplant recipients 





This study, the first of its nature in South Africa, identified the presence of 
CMV UL97 mutations conferring resistance to ganciclovir in the 
haematological oncology, primary immunodeficiency and solid organ 
transplant patients in the Western Cape. The assay successfully detected 
CMV UL97 drug resistance mutations in whole blood and cerebrospinal fluid 
clinical samples. Ongoing viral replication in the background of intensive 
immunosuppression and prolonged antiviral therapy selects for the 
emergence of CMV UL97 drug resistance mutations. 
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Chapter 1.Literature Review 
 
Objectives of the Literature Review 
 
Ganciclovir (and its orally bio-available prodrug valganciclovir) is the only 
antiviral drug available in South Africa for the treatment of cytomegalovirus 
(CMV) disease since its FDA approval in 1981. The antiviral is widely used in 
the haematopoietic stem cell and solid organ transplant setting for the 
treatment and prevention of CMV disease. It has been well documented in 
international literature that prolonged use of ganciclovir is associated with 
development of drug resistance mutations either in the UL97 kinase region or 
in the UL54 DNA polymerase region, necessitating switching of therapy to 
alternate antivirals, namely, foscarnet and cidofovir (Chou, 1999, Strasfeld 
and Chou, 2010, Hall Sedlak et al., 2013, Gohring et al., 2015, Campos et 
al., 2016). 
 
The objective of the literature search was to review the published articles for 
data of CMV drug resistance mutations and identify suitable molecular 
genotypic methods, to allow screening of the local at-risk population groups, 
for CMV UL97 mutations. 
 
Literature Search Strategy 
 
A search was conducted on the electronic database Pubmed, Clinical Key, 
Scopus and Google Scholar. The search terms used were cytomegalovirus, 
human cytomegalovirus, human herpesvirus 5, UL97 drug resistance 
mutations, cytomegalovirus UL97 phosphotransferase mutations, 
cytomegalovirus drug resistance mutations, detection of cytomegalovirus 
UL97 drug resistance mutations, antiviral resistance mechanisms, phenotypic 
UL97 assays, genotypic UL97 assays, CMV in stem cell transplant recipients 
and cytomegalovirus retinitis. 
 
Review articles and book chapters were selected to provide a comprehensive 
understanding of the pathogenesis, diagnosis, treatment approaches and 
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antiviral resistance mechanisms of CMV. Original research articles were 
selected to provide an understanding of prevalence of CMV drug resistance 
mutations, historical testing platforms and advances in rapid molecular 
diagnosis. Articles from 1995 to 2017 were reviewed for this work. 
International data was used for the review to provide a reference. No local 
data was available. References from citations of major publications in the 
field of CMV drug resistance were used to identify relevant articles. 
 
Summary and Interpretation of Literature and its Implications for the 
Research 
 
Genomic Organisation of Cytomegalovirus and Replication 
 
CMV is a 230kbp enveloped double-stranded Beta herpesvirus in the 
Herpesviridae family. The linear genome is enclosed within an icosahedral 
capsid. The proteinaceous tegument is found between the capsid and the 
lipid envelope (Gandhi and Khanna, 2004). 
 
During replication, the immediate early (IE) proteins are expressed on entry 
of the virus into the nucleus. The IE genes are responsible for transcription 
regulation. Early genes (E) are subsequently transcribed and are responsible 
for DNA replication. Late genes that encode for viral structural and assembly 
proteins are then expressed from the replicated genomes (Lurain and Chou, 
2010). 
 
The UL97 kinase (pUL97) is a protein product of gene 97 in the unique long 
region, expressed during early and late CMV replication kinetics. It is 
responsible for the initial phosphorylation of ganciclovir into ganciclovir 
triphosphate, which competitively inhibits viral DNA polymerase (Lurain et al., 
2001, Scott et al., 2004, Drew, 2010). 
 
The normal functions of protein UL97 have not been defined; however, 
deletion of this gene has resulted in a reduced viral yield and severe defects 
in virion morphogenesis and maturation (Lurain and Chou, 2010). These 
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findings suggest that the UL97 protein has a role in regulation of viral DNA 
synthesis. The UL97 protein is also responsible for phosphorylating the 
retinoblastoma protein (pRb), releasing control of cell cycle progression, thus 
creating a favourable environment for viral replication. The nuclear lamina 
component, lamin A/C protein, is also phosphorylated by pUL97, producing 
breaks in the nuclear lamina that are predicted to aid in viral nuclear egress 
(Lurain and Chou, 2010). 
 
Another key protein involved in viral replication and development of CMV 
antiviral resistance is the UL54 protein (DNA polymerase), encoded by UL54 
gene, pUL54 (protein 54 in the unique long region). It is expressed during 
early viral replication, and provides the key functions of DNA polymerisation 
and exonuclease activity (proofreading capabilities) which ensures high 
fidelity replication of the CMV genome and a low mutation rate (Lurain and 
Chou, 2010). 
 
Epidemiology of Cytomegalovirus 
 
CMV is a ubiquitous pathogen. The seroprevalence in developing 
populations is approximately 90% where acquisition occurs predominantly 
early on in life in comparison to developed countries where the 
seroprevalence rate is approximately 40% in adolescents (Griffiths, 2009). 
The mode of transmission is through saliva, sexual contact, in-utero vertical 
transmission (transplacentally), perinatally during delivery, postnatally 
through breastfeeding and during blood transfusion and organ 
transplantation. 
 
CMV has tissue tropism for a wide variety of cells such as fibroblasts, 
epithelial cells, endothelial cells, monocytes and leukocytes (Sinzger et al., 
2008, Renzette et al., 2014). 
 
Following infection, the virus remains latent in episomal form largely in cells 
of the myeloid lineage and reactivates after periods of immunosuppression 
resulting in a productive lytic infection causing CMV end-organ disease. The 
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populations at high risk of CMV disease include solid organ transplant 
recipients, haematopoietic stem cell transplant recipients, HIV-infected 
patients and infants with congenital CMV infection. End-organ disease 
manifests as CMV retinitis, encephalitis, pneumonitis, hepatitis and 
ulcerations in the gastrointestinal tract. Bone marrow involvement is indicated 
by anaemia, neutropenia and thrombocytopenia. Graft rejection and 
susceptibility to bacterial and fungal infections are indirect effects of CMV 
infection post-transplantation (Marr et al., 2002, Nichols et al., 2002, Garcia-
Vidal et al., 2008, Boeckh, 2009, Ariza-Heredia et al., 2014, de la Camara, 
2016). 
 
Antiviral Drugs to treat CMV Disease 
 
There are currently three FDA approved antiviral drugs for the treatment of 
CMV i.e. ganciclovir, cidofovir and foscarnet (Smith et al., 1997b, Strasfeld 
and Chou, 2010). Ganciclovir is a nucleoside analogue of guanosine 
monophosphorylated by the virally encoded kinase pUL97. Host cellular 
enzymes undertake subsequent triphosphorylation into ganciclovir 
triphosphate. Ganciclovir triphosphate inhibits viral DNA polymerase. 
Ganciclovir is not an obligate chain terminator; however, it causes a slowing 
and ultimately cessation of viral DNA chain elongation (Gilbert et al., 2002). 
Ganciclovir is also available in oral form. Its L-valyl ester prodrug 
valganciclovir has a bioavailability of approximately 60% (Pescovitz et al., 
2000). 
 
Ganciclovir use is associated with development of myelotoxicity which is 
reflected by the development of anaemia, leukopenia, thrombocytopenia and 
bone marrow hypoplasia (Strasfeld and Chou, 2010). Cidofovir and foscarnet 
do not require prior phosphorylation. Cidofovir is a phosphonomethoxy 
analogue of cytosine that is converted into the active form by host cellular 
enzymes (Lischka and Zimmermann, 2008, Lurain and Chou, 2010, Strasfeld 
and Chou, 2010, Campos et al., 2016). 
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Foscarnet is a pyrophosphate analogue that binds to and blocks the 
pyrophosphate active site of viral DNA polymerase blocking cleavage of the 
pyrophosphate moiety from deoxynucleotide triphosphates, resulting in 
termination of DNA chain elongation (Lischka and Zimmermann, 2008, 
Strasfeld and Chou, 2010, Campos et al., 2016). 
 
Foscarnet and cidofovir are therefore effective therapies where UL97 
mutations are present; however, their use is limited by their potential to cause 
nephrotoxicity and electrolyte abnormalities (Ljungman et al., 2001, Lurain 
and Chou, 2010, Strasfeld and Chou, 2010, Campos et al., 2016). 
 
Foscarnet and cidofovir are not routinely available in South Africa except 
through Section 5 approval by the Medicines Control Council and therefore, 
not widely used. 
 
Maribavir is an investigational benzimidazole derivative directly targeting 
UL97 kinase, with a favourable side effect profile, in Phase III studies. UL97 
mutations conferring high-level resistance to foscarnet have been 
demonstrated in the kinase ATP binding domain (Chou, 2008, Haidar and 
Singh, 2017). 
 
CMV Infection Management Strategies 
 
There are currently two strategies employed in the transplant setting for 
management of CMV infection, namely the pre-emptive and prophylactic 
approaches. The prophylactic approach involves initiating ganciclovir post 
transplantation prior to reactivation of CMV and development of viraemia. 
This approach is targeted at high-risk patients and aims to reduce the direct 
and indirect effects of CMV. There is, however, a high cost of therapy, drug 
side effects, development of drug resistance and late onset CMV disease 
associated with this approach (Boppana and Britt, 2013, Kir et al., 2017). 
 
Fayek et al (2016) document further reduction of late onset CMV disease in 
donor positive (D+) / recipient negative (R-) kidney transplant recipients by 
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prolonged use of low dose (400mg) valganciclovir for more than 12 months 
without increasing antiviral resistance. 
 
The pre-emptive approach involves initiating therapy after demonstration of 
early CMV viraemia on serial monitoring, thereby reducing unnecessary drug 
treatment. The major disadvantage is the frequent sampling required in these 
patients, the associated costs and inadequacy in patients with asymptomatic 
CMV replication. Good synchronisation and follow-up of results is required in 
this setting. This approach is preferred in haematopoietic stem cell transplant 
recipients to avoid delayed engraftment and bone marrow suppression 
associated with ganciclovir use (Boppana and Britt, 2013, Miller, 2016). 
 
Risk Factors for Emergence of CMV Drug Resistance Mutations in 
Transplant Recipients 
 
The highest risk of CMV disease occurs at 1-3 months post transplantation. 
Additional factors that place transplant recipients at risk of CMV disease 
include donor-recipient serostatus, type and dose of immunosuppression, 
HLA status and ongoing viral replication largely driven by ongoing immune 
suppression. 
 
The type of organ transplanted contributes to risk of developing disease with 
lung and small bowel transplant recipients carrying the highest risk, as a 
result of intensity of immunosuppressive regimens and high amount of 
lymphoid tissue in these organs being transplanted (Gordon et al., 2011, 
Razonable and Humar, 2013, Ramanan and Razonable, 2013, Gohring et 
al., 2015). 
 
Late CMV disease post transplantation occurs after 3 months as a result of 
prolonged defects in cell-mediated immunity (Krause et al., 1997, Boeckh et 
al., 2003, Ozdemir et al., 2007, Boppana and Britt, 2013). 
 
Risk factors for emergence of drug resistance mutations are multifactorial, 
relating to ongoing viral replication in the presence of non-suppressive drug 
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therapy due to viral, host and immune factors (Table 1). In the 
haematopoietic stem cell transplant setting pre-transplantation conditioning 
regimens are used that can be myeloablative or nonmyeloablative, resulting 
in severe immunocompromised states post-transplantation. Solid organ 
transplant recipients also undergo immunosuppressive conditioning 
regimens. Patients are subsequently placed on immunosuppressive drugs to 
prevent graft rejection such as methotrexate, steroids, calcineurin inhibitors, 
tumour necrosis factor inhibitors, monoclonal antibodies and cytotoxic T- cell 
depleting regimens post-transplantation. These immunosuppressant agents 
result in depressed cell mediated immunity, blunted antibody responses and 
leukopenia (Pergam and Jerome, 2010). 
 
Mechanisms of CMV Drug Resistance 
 
Ganciclovir is initially monophosphorylated by pUL97 and subsequent 
triphosphorylation is undertaken by host cellular enzymes into active form, 
ganciclovir triphosphate; which subsequently acts as a competitive substrate 
for DNA polymerase resulting in chain termination of the growing viral strand 
during replication (Strasfeld and Chou, 2010). 
 
Nucleotide sequence changes in UL97 that result in an impairment of 
phosphotransferase activity (initial phosphorylation of ganciclovir) or impaired 
substrate recognition of ganciclovir will result in resistance to ganciclovir 
(Figure 1) (Lurain and Chou, 2010). Isolated UL97 mutations will remain 
susceptible to foscarnet and cidofovir. This is because of differences in drug 
design and mechanism of action - foscarnet is a pyrophosphate analogue 
which does not require prior phosphorylation, whereas cidofovir is a 
monophosphate analogue which only requires cellular kinases for 
diphosphorylation into active form (Lurain and Chou, 2010, Drew, 2010). 
 
The UL54 gene encodes for DNA polymerase, and mutations in this region 
result in reduced antiviral affinity, reduced DNA chain incorporation and 
increased antiviral excision out of the DNA chain (Lurain and Chou, 2010, Le 




Table 1: Summary of risk factors associated with development of CMV drug 
resistance mutations. 
 
Host Factors  Impaired host immunity 
 Donor Recipient serostatus 
                     D+ R –  Solid organ transplant recipients 
                     D-R+ HSCT recipients 
 T- cell depletion 
 Antithymocytes (ATG, OKT3, Alemtuzumab) 
 Steroid administration 
 Type of transplant e.g. lung transplant and 
small bowel have higher risk (Ramanan and 
Razonable, 2013) 
 Underlying co-morbidities 
Viral Factors  Ongoing viral replication due to impaired host 
immunity in presence of non-suppressive 
drug regimens 
 Compartmentalisation in CNS, eye and 
kidney 
 Viral quasispecies 
Drug Factors  Prolonged duration of drug exposure 
 Inadequate dosing 
 Drug potency 
 Bioavailability 
 Poor drug absorption 
 Drug delivery 
 Poor compliance 
D+ R- indicates donor positive recipient negative CMV serostatus; D- R+ 
indicates donor negative recipient positive CMV serostatus. ATG denotes 
antithymocyte globulin. OKT3 denotes anti CD3 antibody. HSCT denotes 
Haematopoietic Stem Cell Transplant. CNS denotes central nervous system. 
 
 
Presence of mutations in UL54 can confer cross-resistance to ganciclovir, 
foscarnet and cidofovir (Lurain and Chou, 2010, Drew, 2010, Gohring et al., 
2015). Isolated UL54 mutations conferring resistance to ganciclovir are rare 
in the absence of UL97 mutations and have only been reported infrequently 
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(Green et al., 2016). UL54 mutations characteristically arise following 
evolution of UL97 mutations. 
 
Mutations secondary to ganciclovir arise in the presence of drug exposure 
and risk factors mentioned above (Table 1). These mutations can accumulate 
over time conferring different levels of resistance. Higher levels of resistance 
are conferred by increasing accumulation of mutations. The clinical 
associations are broad, some mutations have been identified in 
asymptomatic subjects, whereas some have been identified in patients with 
life threatening and severe disease, and some in subjects who have 
subsequently become virologically suppressed on treatment (Lurain and 
Chou, 2010). 
 
Diagnosis of CMV UL97 and UL54 Mutations 
 
The presence of CMV drug resistance mutations can be suspected in 
patients who show an increase or plateauing of CMV viral load levels while 
being exposed to adequate and regular doses of ganciclovir. A lack of clinical 
response of CMV disease is also suggestive of the presence of drug 
resistance mutations (Drew, 2010). Genotypic assays are preferred due to 
expedited result availability. 
 
Phenotypic and marker transfer studies are traditional methods utilised to 





Phenotypic assays measure the concentration of drug required to reduce 
viral growth in cell culture systems by 50% (IC50) or alternatively by 90% 




Figure 1. Map of UL97 gene. Ganciclovir resistance mutations resulting in 
impaired phosphate transfer or substrate recognition are indicated in blue. 
Maribavir resistant mutations indicated in red. GCV indicates ganciclovir. 




The former is preferred due to better reproducibility (Eckle et al., 2004, 
Strasfeld and Chou, 2010). 
 
The gold standard for diagnosis of CMV drug resistance mutations is the 
plaque reduction assay (PRA). This involves inoculating virus into cell culture 
and introducing drug at varying concentrations. Viral growth is measured 





The plaque reduction assay is limited by its labour intensiveness, poor 
standardisation in terms of culture conditions, viral plaque definition and 
enumeration of plaques. These factors are directly influenced by viral 
inoculum and drug concentration range. Laboratory strains of CMV have 
different growth characteristics to wild type patient strains i.e. show a faster 
replication rate due to mutations generated during serial passage, therefore, 
they may not be effective when used as control strains for these assays. The 
plaques generated by mutant viruses develop slowly and are usually smaller 
than plaques from control virus cell counterparts due to extracellular high 
passage laboratory strains having different replication kinetics compared to 
cell associated clinical strains (Lurain and Chou, 2010). 
 
The time to result of plaque reduction assays can take more than four weeks, 
resulting in delays in patient management and clinical decision-making. 
There are a few laboratory facilities equipped to run and maintain cell culture 
facilities. This facility is only found at research laboratories. In South Africa, 
Western Cape, there is one laboratory with cell culture facilities for academic 




Genotypic assays involve utilising polymerase chain reaction (PCR) to 
amplify the region of interest (UL97 kinase/UL54 DNA polymerase) where 
mutations are known to occur from various samples such as tissue, blood, 
plasma, vitreous fluid and cerebrospinal fluid (CSF). Various PCR design 
platforms are used ranging from conventional PCR (one step, nested) (Lurain 
et al., 2001, Hu et al., 2002, Jabs et al., 2006, Castor et al., 2007), real time 
PCR (Gohring et al., 2006, Castor et al., 2007, Volfova et al., 2014) detection 
using hybridisation probes, or melting temperature analysis (Chen et al., 
2015). 
 
Sanger sequencing or next generation sequencing methods determine the 
nucleotide sequence. Sanger sequencing is limited in that viral populations 
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representing more than ten to twenty percent of the viral population in the 
sample can be detected (Chou et al., 2014). 
 
Improved detection of minority variants can be attained through next 
generation sequencing (Kampmann et al., 2011, Benzi et al., 2012, Sahoo et 
al., 2013, Chou et al., 2014). 
 
The nucleotide sequence is then analysed for the presence of nucleotide 
differences at key codons of interest to identity single or multiple mutations. 
The level of resistance, cross-resistance or sensitivity is then assessed using 
the Ulm University Mutation Resistance Analyzer database and published 
findings (Chevillotte et al., 2010). 
 
Interpretation of genotypic assays is challenging with regard to correlation 
with clinical outcomes (Boivin et al., 1996, Perez, 1997, Eckle et al., 2000), 
effect of single versus multiple mutations, presence of mixed viral populations 
and assay sensitivity in detecting minority viral variants (Chou, 2001, Jabs et 
al., 2003, Gilbert and Boivin, 2003, Ducancelle et al., 2004, Jabs et al., 
2006). 
 
Higher viral load levels, delayed viral clearance requiring prolonged treatment 
duration and severe clinical outcomes are associated with mixed viral 
populations in solid-organ and allogeneic stem cell transplant recipients 
(Humar et al., 2003, Coaquette et al., 2004, Manuel et al., 2009, Vinuesa et 
al., 2017). 
 
Presence of multiple low-level variants can contribute to a drug-resistant 
phenotype (Chou et al., 2014). Detection of these low-level mixed drug 
resistant mutations is associated with poorer outcomes (Houldcroft et al., 
2016). 
 
Next generation sequencing methods reproducibly detect low abundance 
resistance mutations not reported by conventional sequencing (Sahoo et al., 
2013). Additional advantages include earlier detection of drug resistant 
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mutations, monitoring the complex evolution of mutations missed by Sanger 
sequencing and increased sequencing depth that allows for detection of 
mutant viral subpopulations that evolve with changing antiviral therapy (Chou 
et al., 2014). 
 
Marker Transfer Studies 
 
Marker transfer studies, also known as recombinant transfer studies, are 
employed to phenotypically confirm genotypic mutations. Mutations detected 
genotypically are introduced into cell culture control laboratory strains 
through either homologous recombination by co-transfection, recombination 
of cosmic clones or genetically modified control strains to demonstrate the 
effect on viral growth. Growth capacity and drug susceptibility of these 
recombinant strains is then assessed (Chou, 2010, Drouot et al., 2014). 
Some published mutations detected genotypically have not been 





Identification of Gaps or Needs for Further Research 
Ganciclovir has been unequivocally documented to be associated with 
development of drug resistance mutations, which can adversely affect clinical 
outcomes, not only due to presence of mutations and response to treatment, 
but also - due to underlying risk factors for CMV replication and disease. A 
large body of work in this arena has been generated from HIV/AIDS infected 
patients with CMV retinitis (Jabs et al., 2006, Strasfeld and Chou, 2010), 
stem cell transplant recipients (Schnepf et al., 2013, Choi et al., 2014, 
Gohring et al., 2015) and solid organ transplant recipients particularly kidney, 
lung, renal and cardiac transplant recipients (Boivin et al., 2005, Nogueira et 
al., 2006, Reddy et al., 2007, Garcia-Martinez et al., 2008, Iwasenko et al., 
2011, Yost et al., 2014, Minces et al., 2014). 
 
Since the introduction of highly active antiretroviral therapy (HAART) the 
prevalence of CMV UL97 drug resistance mutations in HIV-infected patients 
has declined from more than 20% to approximately 5% (Jabs et al., 1998, 
Martin et al., 2007, Lurain and Chou, 2010). 
 
The solid organ transplant population has been documented to have a higher 
prevalence of drug resistance mutations ranging between 5-10% (Lurain and 
Chou, 2010), depending on various risk factors such as donor–recipient CMV 
serostatus, duration on ganciclovir, prophylactic or pre-emptive approach 
employed and type of immunosuppressants prescribed. Stem cell transplant 
recipients in contrast have been shown to have a 0-4% risk of developing 
CMV UL97 drug resistance mutations (Boivin et al., 2004, Boivin et al., 2005, 
Boivin et al., 2009). 
 
Genetic polymorphisms of unknown clinical significance as well as UL97 
mutations associated with hypersusceptibility to ganciclovir have also been 
identified, particularly in stem cell transplant patients (Tanaka et al., 2011, 
Boutolleau et al., 2011). Some UL97 mutations are described as genetic 
markers in certain Asian countries, suggesting that these mutations are wild 
type sequence variants (Tanaka et al., 2011, Sun et al., 2012, Zhang et al., 
2013, Lee et al., 2013). 
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There is no local data on the magnitude of CMV drug resistance mutations in 
South Africa despite the extensive use of ganciclovir. Prevalence of CMV 
UL97 drug resistance mutations in the local risk groups needs to be 
established to elucidate whether the epidemiology is similar to that in 
international literature. The prevalence of these mutations could be utilised 
indirectly as an indication of prescribing practices in the different sectors, i.e. 
therapeutic versus pre-emptive and extent of use of ganciclovir in different 
transplant settings. Additional factors that may contribute to the lack of 
significant decline in CMV viral load levels include drug bioavailability, 
inadequate dosing or poor compliance. Hence, clinical profiles and outcomes 
need to be documented. 
 
UL97 mutations have been detected in different body compartments such as 
vitreous fluid and CSF, affecting clinical outcome in patients with CMV 
retinitis and transplant recipients with CMV encephalitis (Boivin et al., 1997, 
Julin et al., 2002, Jabs et al., 2003, Kuo et al., 2003, Imai et al., 2004, Jabs et 
al., 2006, Miller et al., 2006, Hoang et al., 2010, Arslan et al., 2010). 
 
The presence of drug resistance mutations in certain tissue compartments, 
but not in blood, as demonstrated in the literature, may suggest better 
penetration of ganciclovir in certain tissue compartments. The implications 
that this may have on disease outcomes and response to treatment needs to 
be further explored, particularly to address sufficient drug dosing trends and 
duration of therapy to avoid selecting for drug resistance mutations (Frange 
et al., 2013, Gohring et al., 2015). 
 
There are no studies in our setting on patients with retinitis as treatment 
outcome is usually largely graded on clinical appearance. In severely 
immunocompromised HIV-infected patients with CMV retinitis who have 
delayed immune reconstitution, and have been treated with ganciclovir for 
prolonged periods, there could potentially be an undiagnosed pool of patients 
who develop CMV UL97 drug resistance mutations. Despite the new change 
of CD4 threshold with initiation of antiretroviral therapy at higher CD4 levels, 
this scenario may theoretically apply to severely immunocompromised 
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patients with delayed antiretroviral treatment initiation, who are on prolonged 
treatment for CMV retinitis. 
 
The local cohort of transplant recipients remains a high-risk category for 
development of drug resistance mutations, hence, it is important to establish 
a baseline of prevalence and document clinical outcomes where possible. 
This may be even more relevant in the future, depending on evolution of 
mutations and their impact on clinical outcomes and therapeutic options 
available. Ganciclovir is currently not a restricted drug because its use is 
confined to specific risk groups where treatment is indicated. There are no 
established local studies documenting the extent of CMV drug resistance 
mutations. Personal communication with Prof. Alan Davidson and Dr. P. 
Nourse (Red Cross War Memorial Children’s Hospital, Haematology-
Oncology Department) suggested that the presence of these mutations is an 
insignificant problem. 
 
This raises the question of whether, in the setting of high prevalence of highly 
resistant mutations, this agent should be restricted. Alternatively, its use 
closely monitored for development of mutations in high-risk populations with 
antiviral substitution where applicable. This would, however, require open 
dialogue amongst relevant stakeholders, effective cost management, 
appropriate testing strategies, effective use of limited resources, skilled 
laboratory personnel to perform the test and skilled clinical interpretation of 
genotypic results within the background of an appreciation of the role of 
underlying clinical disease driving CMV replication and impaired host 
immunity. 
 
A large amount of resources is invested into the transplant setting to ensure 
graft survival and improved morbidity. The overall cost-benefit analysis would 
have to be weighed carefully and tailored to our unique setting based on 
extensive systematic data collation. 
 
With this study, we aim to provide a brief preliminary assessment of the 
presence of these mutations in our population, which has never been 
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documented locally, identify the clinical groups at highest risk for 
development of drug resistance mutations and provide a platform for further 
studies on this subject. 
 
Future studies could additionally explore the prevalence and evolution of 
UL97 mutations in patients with previous acyclovir exposure followed by 
ganciclovir exposure. These would include haematopoietic stem cell 
transplant and solid organ transplant recipients who receive acyclovir for 
prophylaxis against Herpes Simplex Virus and CMV followed by ganciclovir 
routinely in the post-transplant period. In vivo and in vitro evidence is 
provided by several studies. 
 
Erice et al (1998) demonstrated the presence of CMV UL97 mutations in four 
isolates of haematopoietic stem cell transplant recipients due to exposure to 
acyclovir followed by ganciclovir and absence of mutations in those with 
exposure only to acyclovir. This suggests rapid evolution and possible 
predisposition due to using acyclovir prior to ganciclovir. Acyclovir has 
minimal activity against CMV and this may lead to emergence of mutations 
because of partially suppressive drug pressure. 
 
The emergence of CMV drug resistance mutations has been documented in 
solid organ transplant recipients following exposure to valaciclovir and 
ganciclovir (Alain et al., 2004, Hantz et al., 2005). 
 
Michel et al (2001) have further provided in vitro evidence substantiating the 
phenomenon of acyclovir selecting out mutations to ganciclovir. 
 
Knowledge of the local epidemiology of CMV drug resistance mutations 
through documentation of case series and descriptive research studies is 
essential towards informing on current clinical practices and improving 
patient outcomes. This can be achieved by improving access to alternative 
therapies and improved diagnostic services portfolios, which are largely 
driven, amongst other factors, by burden of disease, clinical utility in 
diagnosis and prognostic value of diagnostics tests within a cost-effective 
22 
 
framework. Towards this end, baseline prevalence needs to be accurately 
established and documented. 
 
Future studies could additionally attempt to better document clinical 
outcomes, ganciclovir prescribing practices in the various sectors; explore 
the impact of ganciclovir pharmacokinetics, drug bioavailability and host risk 







The development of drug resistance mutations is a well-described 
phenomenon in the treatment of cytomegalovirus (CMV) infection in stem cell 
transplant and solid organ transplant recipients. The selection of drug 
resistance mutations is multifactorial, considerably driven by host and viral 
factors such as viral replication in the presence of severe 
immunosuppression and prolonged drug exposure. 
 
CMV drug resistance mutations are localized to the UL97 (kinase) gene and 
the UL54 (DNA polymerase) gene. Mutations occur in response to treatment 
with ganciclovir, a nucleoside analogue of guanosine and its oral prodrug 
valganciclovir. Prolonged exposure to cidofovir - a monophosphate 
nucleotide analogue and foscarnet - a pyrophosphate analogue, results in 
mutations in the UL54 gene. These drug resistance mutations are thought to 
evolve over time with progressive accumulation, initially in the UL97 gene 
and subsequently in the UL54 gene. Cases of UL54 drug resistance 
mutations in the absence of UL97 mutations are rare. These mutations either 
result in impaired phosphorylation of ganciclovir, changes in the substrate 
recognition sites or exonuclease activity and thus a continuous rise or 
plateau in the CMV viral load consequent to continued viral replication 
despite adequate drug therapy. 
 
Clinical implications vary from asymptomatic disease to progressive disease 
and adverse outcomes due to CMV disease progression. This paper aims to 
demonstrate the prevalence of CMV UL97 drug resistance mutations in the 
local cohort of at-risk groups treated with ganciclovir. 
 
The motivation behind the study is lack of data in most low and middle-




2.2. Aims and Objectives 
 
This study aimed to document and characterise the prevalence of CMV drug 
resistance mutations in the targeted population groups at risk of CMV 
disease and the development of CMV UL97 drug resistance mutations i.e. 
HIV- infected patients, solid organ transplant patients and haematopoietic 
stem cell transplant recipients in Cape Town, South Africa. 
 
The objectives of the study were to: 
1. Identify retrospective patient samples and prospective clinician-
referred patients with elevated CMV viral load levels, suggestive of 
possible ganciclovir resistance. 
2. Amplify and sequence CMV UL97 gene to identify UL97 drug 
resistance mutations. 
3. Describe the prevalence of CMV UL97 mutations in the population 
sampled. 
4. Describe the clinical history and outcomes in prospective clinician-
referred patients with CMV UL97 mutations. 
 




Ethical approval for this study was obtained from the Human Research Ethics 
Committee University of Cape Town (HREC REF: 655/2015). 
2.3.2 Samples and Source Population 
 
The study was a descriptive study, which had two components. The first 
component being a retrospective cross-sectional study to investigate the 
prevalence of CMV UL97 mutations in transplant, oncology and HIV- infected 
patients treated with ganciclovir and have shown elevated serial CMV viral 
load levels. Extracted DNA previously used for CMV viral load testing, stored 




Thirty-three (33) samples were identified through a search of the archived 
CMV viral load results on the National Health Laboratory Service (NHLS) 
laboratory information system (LIS) at Groote Schuur Hospital. 
The Groote Schuur Hospital NHLS laboratory provides a secondary level of 
service to surrounding secondary and tertiary hospitals in the Metro-East 
District in the Western Cape. 
 
Data from 2010-2016 was used to identify trends in CMV viral load levels. 
Serial CMV viral load results were analysed for increasing or plateauing 
trends. Clinical parameters such as diagnosis, sample type and location of 
patient were reviewed during the selection of samples (Table 2). 
 
The second component was a case-series utilising data from patients on 
whom CMV drug resistance was suspected who were referred by clinicians 
for testing based on CMV infection, risk factors, treatment with ganciclovir 
and poorly responsive CMV viral load levels despite adequate ganciclovir 
dosing. This data was collected prospectively. Eight (8) patients were 
enrolled for this prospective component. 
 
2.3.3 Assay validation 
 
Prior to testing of patient samples, the assay was optimised on extracted 
DNA that had been tested for CMV viral load, as well as on samples from an 
external quality assurance body, Quality Control of Molecular Diagnostics 
(QCMD), with detection of 100% of UL97 mutations that were present in the 




Following retrieval of the extracted nucleic acid, conventional nested PCR 
amplification of the UL97 gene of CMV was performed using a set of 
published primers and thermocycling reaction conditions which amplifies 
codons 433 to 683 of the 2124 bp UL97 gene (Hu et al., 2002). Although all 
reported CMV UL97 mutations occur between codon 400 to codon 707, 
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clinically relevant mutations occur between codon 460 and codon 607 of 
CMV UL97 gene. This region was sufficiently covered by the assay (Lurain et 
al., 2001).This method was selected on the basis of being shown to 
effectively amplify the CMV UL97 gene on a variety of samples (cell culture, 
urine, plasma, CSF and vitreous fluid). The nested design allows for 
improved sensitivity. 
 
Verification of a 707 bp PCR product was performed on 1% agarose gel 
electrophoresis stained with ethidium bromide and visualised under UV 
illumination in the presence of a molecular weight marker to confirm correct 
band size and quality prior to sequencing. One negative and one positive 
control was included in every batch of PCR reactions. The negative control 
served to monitor and identify potential contamination. The positive control 
was not sequenced. 
2.3.5 Sequencing and Sequence Analysis 
 
Sample clean up and Sanger sequencing was performed at an external 
facility, Inqaba Biotechnologies, using the inner PCR primers. The samples 
were sequenced bidirectionally using both forward and reverse primers. 
Sequence quality was analysed by assessing electropherogram peaks, 
signal strength, level of background noise and presence of artefacts. Poor 
quality sequences were rejected for analysis. 
 
Sequences were edited using Finch TV for base calling (Finch TV 1.4.0, 
Geospiza, Inc.; Perkin Elmer Informatics, Seattle, WA, USA; 
http://www.geospiza.com). Bio-Edit Sequence Alignment Editor version 
7.1.3.0 was used for manual sequence editing (Hall, 1999) and alignment 
using ClustalW version 1.4 (Thompson et al., 1994). Subsequently, the 
sequences were submitted in FASTA format to the Ulm University MRA-
mutation resistance analyzer online database (AG Bioinformatics and 
Systems Biology, Institute of Neural Information Processing Institute of 
Virology) for presence of CMV UL97 mutations (Chevillotte et al., 2010) . This 
online tool aligns the sequence to the gene of interest and provides a report 
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on published mutations at key codons of UL97 where mutations are known to 
occur; with reference to the TB40-BAC4 CMV strain, a bacterial artificial 
clone of the TB40E lab adapted endotheliotropic CMV strain (Murrell et al., 
2016). 
 
Sequences were submitted to the NCBI Basic Local Alignment Search tool 
(BLAST) for comparison with other published sequences and to ensure that 
the desired gene sequence product was isolated. The percentage of 
sequence identity of the submitted sequence against other CMV sequences 
in the database, the closest match and areas of nucleotide differences were 
assessed. 
 
2.3.6 Interpretation and Analysis 
 
The Ulm University MRA-Mutation Resistance Analyzer database provides a 
report detailing the alignment of the submitted CMV UL97 sequence, the 
region covered as well as presence of insertions and deletions.(Chevillotte et 
al., 2010). See Appendix V for patient reports. 
 
Mutations associated with ganciclovir resistance at key CMV UL97 codons 
were analysed. The IC50 ratios based on cell culture experiments were 
reported for ganciclovir resistant strains. Wild type strains were reported as 

















































Figure 2 CMV genotypic testing workflow. Schematic diagram representing 
sample identification, testing and analysis to result of CMV drug resistance 
mutations. PCR indicates polymerase chain reaction. 
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33/41 (80%) of these samples were retrospective samples from patients who 
were tested based on sequentially elevated CMV viral load results as per 
information obtained from the laboratory information system (LIS) database 
and 8/41 (20%) of patients were from patients referred by clinicians on 
suspicion of presence of possible CMV UL97 drug resistance mutations. The 
median age of all patients tested in the study was 19 years (IQR 1-65); 22 
(54%) were female and 19 (46%) male. 
 
The median viral load of all samples tested was 5600 copies per millilitre 
(cps/ml), median log value 4.12. Of 9805, CMV viral load records reviewed 
between 2009 and 2015, 318 (3%) records had consecutive viral load results 
that were elevated. The patients were separated into categories based on 
their clinical diagnosis as captured on the NHLS laboratory request form. 
There were four categories, namely HIV-infected, Solid Organ Transplant, 
Haematological Oncology and Unknown Diagnosis. 
 
23/41 (56%) patients were grouped in the Haematological Oncology 
category, 10/41 (24%) patients in the Solid Organ Transplant category, 6/41 
(15%) patients were HIV-infected and 2/41 (5%) patients had no clinical 
diagnosis recorded on the form and therefore in the “Unknown Diagnosis” 
category (Table 2). 
 
Detailed description on the characteristics of patient categories, patient 
sample characteristics and source of referral is provided in Table 2. 
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Retrospective Samples Clinical Patients 
Number  41 33  8 
Age –Mean 
           Median (Range) 
 21.7 




 2.5 (1-19) 
Male-no. (%)  19 (46) 16 (48)  3 (38) 
Female-no. (%)  22 (54) 17 (52)  5 (62) 
Sample Type 
        Cerebrospinal fluid 










Diagnostic Categories-no. (%) 
           Solid Organ Transplant 
           Haemat-oncology 
           HIV Infection 
           Unknown Diagnosis 
 
 10 (24) 
 23 (56) 
 6 (15) 







 1 (12) 
 4 (50) 
 3 (38) 
 
CMV Viral Load (Mean) 
           Copies/ml 
           Log value 
 








 166 7225  
 5.48 
Hospitals: no.  (%) 
           Red Cross Children’s 
           Hospital 
           Groote Schuur Hospital 
           UCT Private Hospital 
           Tygerberg Hospital 
           Other 
 
 17 (41) 
 
9 (22) 
 8 (20) 





 8 (24) 















Of the 41 patient samples amplified and sequenced, 8 patients (20%) had 
documented CMV UL97 mutations (Table 3). 3/8 (38%) of samples in the 
clinician referred group had documented CMV UL97 drug resistance 
mutations, namely H520Q, L595S, C592G and C603W. The C592G and 
C603W mutations were identified in one patient (Patient C and Table 3). 
 
5/8 (63%) mutations were detected in the retrospective patient group. 
Amongst the retrospective samples, 5/33 (15%) had documented CMV UL97 
drug resistance mutations. The mutations identified were M460V, C592G, 
Q449K and D605E. 
 
In total, seven mutations were identified, namely H520Q, L595S, C592G, 
C603W, M460V, D605E and Q449K (Table 3a). 
 
The C592G mutation was identified in two patients, one in the retrospective 
patient group and another in the clinician referred group. The D605E 
mutation, detected in two stem cell transplant recipients in the retrospective 
patient group, is a genetic polymorphism of unclear phenotype. This mutation 
constituted 1/7 (14%) of all mutations (Table 3 and Table 3b). 
 
According to diagnostic category, the majority of CMV UL97 mutations, 7/41 
(17%) were found in patients in the Haematological Oncology category and 
1/41 (2.43%) of patients in the Solid Organ Transplant category (Table 2). 
 
These findings suggest the presence of CMV UL97 mutations, not only as 
sequence variants, but also as resulting in resistance to ganciclovir in the 
local adult and paediatric setting. There was a higher prevalence in patients 
with haematological malignancies and patients with primary 
immunodeficiency disorders. 
 
Haematological oncology patients seem to be at a higher risk of CMV UL97 
drug resistance mutations in proportion to solid organ transplant recipients 
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and HIV infected patients, although this risk is not statistically significant 
(P=0.306). 
 
Phylogenetic analysis of the UL97 gene sequences showed high 
conservation in this area, confirming the findings of Lurain et al (2001). 
Genotypic variation of CMV requires analysis of UL55, UL73 and UL75 
genes (Chou, 1992, Tarrago et al., 2003, Pignatelli et al., 2003). Therefore, 
the nucleotide base and amino acid differences between the sequences were 
better represented in the highlighter plot (Figure 4 and Figure 5). The 
highlighter plot was constructed by submitting aligned sequences to an online 
service available at www.hiv.lanl.gov . The sequences were compared to 




Table 3 Patient clinical parameters and CMV UL97 mutations identified. 
 




GANCICLOVIR SAMPLE TYPE 
PATIENT A 3 Myelodysplasia 
 
271 900(log 5.43) L595S Resistant 
4.9-8.5x 
Whole blood 
PATIENT B 2 Pre-B Acute Lymphoblastic 
Leukaemia 
877 6224 (log 6.70) H520Q Resistant 
5.2-10x 
Whole blood 





PATIENT D 32 Multiple Myeloma 4100 (log 3.61) M460V Resistant 
5.5-9.8x 
Whole blood 
PATIENT E 38 Acute Myeloid Leukaemia 11 950 (log 4.08) D605E Sensitive 
0.6-0.9x 
Cerebrospinal fluid 
PATIENT F 46 Chronic Myeloid Leukaemia 12 650 (log 4.10) Q449K Sequence variant  Whole blood 
PATIENT G 40 Acute Myeloid Leukaemia 1064 (log 3.00) D605E Sensitive 
0.6-0.9x 
Whole blood 


















 Histidine Glutamine 
L595S 
 
 Leucine Serine 
C592G 
 
 Cysteine Glycine 
C603W 
 
 Cysteine Tryptophan 
M460V 
 
 Methionine Valine 
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Figure 3 CMV UL97 mutations detected as per diagnostic category in 41 
samples tested. HAEMAT-ONCOL indicates Haematological Oncology , SOT 




Figure 4: Nucleotide highlighter plot indicating nucleotide base differences in 
comparison to master sequence CMV AD169 (CMVAD169m). Nucleotide 
differences are indicated by different colours. Green bar indicates adenine, 
blue indicates cytosine, orange indicates guanine, red indicates thiamine and 
royal blue indicates IUPAC mixtures. A indicates the clinician referred group 






Figure 5 Amino acid highlighter plot indicating amino acid differences in 
comparison to master sequence CMV AD169 (CMVAD169m). A indicates the 





Ambiguous nucleotide bases indicated in black Patient C sequence 
contained ambiguous nucleotide bases indicated in black.www.hiv.lanl.gov  
Key (www.hiv.lanl.gov): 
 His(H)   Asp(D) Glu(E)   Lys(K) Asn(N) Gln(Q) Arg(R)  
 Met(M)   Ile(I) Leu(L) Val(V)   Phe(F) Trp(W) Tyr(Y)  
 Cys(C)   Ala(A) Gly(G) Ser(S) Thr(T)   Pro(P)  
 Other   Gap    
 
3.3 Case Reports and Discussion 
 
Three paediatric patients in the clinician-referred group are presented in 
detail to highlight the individual underlying host risk factors for CMV 
replication necessitating prolonged ganciclovir/valganciclovir treatment and to 




Non-fatal CMV Reactivation in a Post-Haematopoietic Stem Cell 
Transplant Recipient 
 
Patient A was an HIV-negative 3-year-old child at time of transplantation in 
March 2014. He was diagnosed with congenital myelodysplasia a few 
months after birth. The donor was CMV serostatus IgG negative, recipient 
CMV serostatus IgG positive. The recipient’s conditioning regimen prior to 
transplantation included etoposide and dexamethasone. Valaciclovir 
prophylaxis and cyclosporin A was initiated in the immediate post-transplant 
period. He had post-operative complications of Gram-negative sepsis 
secondary to Acinetobacter jejunii and CMV reactivation with possible CMV 
pneumonia. Successful engraftment occurred on day 11 post transplantation. 
 
Ganciclovir was commenced on day 19 post transplantation in response to 
CMV viremia. He was re-admitted for intravenous ganciclovir on multiple 
occasions following elevated CMV viral load levels interspersed with oral 
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courses of valganciclovir. The total duration of ganciclovir and valganciclovir 
received was seven months post-operatively. 
 
Genotypic testing performed on day 70 post transplantation, at a viral load of 
271 900 cps/ml (log value 5.43) revealed the L595S (leucine to serine at 
codon 595) mutation. This mutation is associated with high resistance (2.3-
3.9x) to ganciclovir compared to wild type strains (Boivin et al., 2009). 
However, subsequent CMV viral load levels declined (Table 3, Figure 4, 
Figure 5 and Figure 6). This co-incided with the reduction in dosage of 
cyclosporin. He is currently thriving, off immunosuppressant drugs and 
receiving his routine childhood immunisations. 
 
It has been shown that drug resistance mutations can disappear as a result 
of cessation of drug pressure removing selection for these mutations or as a 
result of decreasing immunosuppressant drugs i.e. strengthened host 
immunity (Boivin et al., 2012, Volfova et al., 2014). The presence of quasi-
species could also be a contributing factor (Iwasenko et al., 2007, Renzette 
et al., 2013, Renzette et al., 2014). 
 
CMV displays significant human inter-host variability and intra-host diversity, 
with as many as six genotypes observed within one single patient on ultra-
deep pyrosequencing (Gorzer et al., 2010, Renzette et al., 2014). Various 
mechanisms are proposed. These include generation of de novo mutations 
during replication following primary infection, although the DNA polymerase 
proofreading function should limit these mutations. 
 
Another theory relates to the introduction of new strains through re-infection; 
however; this theory does not explain the diversity in congenitally infected 
neonates (Renzette et al., 2014). 
 
During dissemination to distal compartments, the viral population can rapidly 
evolve, either due to natural selection or population bottlenecks, leading to 
populations in the distal tissues or organs being genetically differentiated 
from the peripheral blood compartment. This phenomenon is known as 
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compartmentalization. The populations in the distal compartments are also 
less genetically diverse than those in the peripheral blood. Once CMV has 
disseminated to compartments or if the virus remains in the peripheral blood, 
the populations become relatively stable and many mutations remain at 
similar frequencies over time (Renzette et al., 2014). Compartmentalization 
can be reflected by differences in the distribution of drug resistance-
genotypes observed in some patients within the different compartments (Prix 
et al., 1999, Eckle et al., 2000, Hamprecht et al., 2003, Frange et al., 2013, 






































































































































































































































































































Figure 6 Timeline illustrating CMV viral load trend and detection of UL97 
mutations in Patient A over a seven-month period of 
ganciclovir/valganciclovir post-transplantation. IV indicates intravenous. 
 
Patient B  
 
Fatal Outcome in a Patient with Pre-B Acute Lymphoblastic Leukemia 
with CMV Infection 
 
Patient B was a 2-year-old patient with pre-B acute lymphocytic leukemia 
diagnosed at the age of 3 months in 2013. He underwent chemotherapy 
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successfully and went into remission. Whilst on maintenance chemotherapy, 
started in February 2014, he developed recurrent infections, persistent 
severe lymphopenia, intermittent thrombocytopenia, absent immunoglobulins 
and CMV viremia. He received polyvalent human normal immunoglobulin 
infusions (Polygam®). Intravenous ganciclovir was initiated followed by oral 
valganciclovir for three weeks. Ganciclovir was re-initiated following a 
rebound in CMV viral load on 7/01/2015. There was no evidence of CMV end 
organ disease on colon biopsy sample and opthalmoscopy. 
 
Patient B was classified by attending medical personnel as having a poor 
prognosis for his underlying condition based on age at diagnosis of acute  
lymphoblastic leukemia, a high white cell count at diagnosis, a severe 
immunodeficiency and the t (4; 11) translocation. 
 
He had persistently elevated CMV viral load levels ranging between 794 500 
cps/ml (5.9 log) and 66363888 cps/ml (log 7.8) over a period of five months. 
Genotypic testing on day 104 of ganciclovir, at a viral load of 11 950 cps/ml 
(log 4.08) revealed the H520Q mutation (histidine to glutamine at codon 520) 
associated with 5.2-10x resistance to ganciclovir (Table 3, Figure 4, Figure 5 
and Figure 7). 
 
Attempts to attain Foscarnet were initiated through the Medicines Control 
Council; however; he demised following the development of neutropenic 















































































































Figure 7 Timeline illustrating CMV viral load trend in Patient B. CMV viral 






Asymptomatic Patient with an X-linked Primary Immunodeficiency and 
Multiple UL97 Drug Resistance Mutations 
 
Patient C was a 3-year-old HIV-negative patient diagnosed at four months of 
age with Wiskott-Aldrich syndrome, an X-linked autosomal recessive primary 
immunodeficiency disease characterised by recurrent bacterial infections 
eczema and bleeding tendencies caused by thrombocytopenia and platelet 
dysfunction. He received ganciclovir for more than a year for CMV viremia 
following ICU admission for presumed CMV pneumonia. Initial genotypic 
testing for UL97 mutations after a period of 5 months on ganciclovir showed 
the absence of UL97 mutations i.e. wild type CMV (Figure 8). Biopsy 
samples of duodenum, stomach and oesophagus revealed eosinophilic 
gastritis. 
 
Subsequent testing 19 months after the first genotypic test, 22 months on 
valganciclovir, revealed two mutations in the UL97 gene namely, C592G 
(cysteine to glycine at codon 592) and C603W (cysteine to tryptophan at 
codon 603). 
 
This patient experienced multiple episodes of dysentery, dermatitis, upper 
and lower respiratory tract infections. There was no evidence of CMV end-
organ disease. At the time of publication, he had not undergone stem-cell 
transplantation due to parental refusal. He continued receiving regular clinical 
follow-up visits, polyvalent immunoglobulin injections (Beriglobin®), 
prednisone and fluconazole and co-trimoxazole prophylaxis. Following 
detection of CMV UL97 mutations ganciclovir and prednisone was stopped 









































































































































































































































Figure 8 Timeline illustrating CMV viral load trend and evolution of UL97 
mutations in Patient C over an eighteen month period of valganciclovir. 
 
Patient D - Patient H were in the retrospective patient group, no clinical 
history was available other than diagnosis provided on laboratory test request 
form (Table 3, Figure 4 and Figure 5). 
3.4 Other UL97 Drug Resistance Mutations 
 
The C592G (cysteine to glycine at codon 592) and M460V (methionine to 
valine at codon 460) are ganciclovir resistant mutations that were detected in 
retrospective patient samples on which clinical history was not available, the 
former being a renal transplant candidate and the latter a patient with multiple 
myeloma (Table 3, Figure 4 and Figure 5). 
 
3.5 Sequence Variants/Genetic Polymorphisms 
 
The D605E mutation sequence polymorphism (aspartic acid to glutamic acid 
at codon 605) confers sensitivity to ganciclovir. It has been described in 
treatment naïve and treatment exposed persons. In some countries, such as 
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Asia, a higher prevalence was found compared to European countries (Chou, 
2008, Sun et al., 2012, Sung et al., 2012). 
 
The Q449K (glutamine to lysine at codon 449) mutation has only been 
identified as a sensitive genetic polymorphism of uncertain clinical 
significance. In our study, this mutation was identified in a patient with 
chronic myeloid leukaemia. According to the University of Ulm MRA 
database this mutation has been isolated in a patient previously treated with 
acyclovir without any exposure to ganciclovir, suggesting that this mutation 
also occurs naturally among clinical CMV isolates (Erice et al., 1998, Lurain 




3.6.1 Sample Size 
 
There were limited samples available in the prospective clinician referred 
group of the study. The current impression (personal communication) among 
clinicians in the transplant setting, is that CMV UL97 drug resistance 
mutations are not a significant problem, hence referral was poor. The 
historical lack of diagnostic assays to detect CMV UL97 mutations 
contributes to limited sample referral. 
 
3.6.2 Lack of Clinical Correlation 
 
The majority of retrospective samples in which mutations were identified do 
not have a clear, concise clinical history, risk factors and outcomes. 
Phenotypic correlation could not be assessed in these samples. Subsequent 
declines in CMV viral load levels to clinically acceptable levels, in the setting 
of ongoing immune suppression and adequate ganciclovir dosing, could be 





The inability to test multiple samples at different timepoints, in different  
compartments based on clinical history where indicated further limits the 




Sanger sequencing is known to detect viral populations present more than 
20% of the total viral population in the sample (Chou et al., 2014). We cannot 
entirely exclude the presence of minority variant subpopulations with drug 
resistance mutations. Detection of wild type sequences does not exclude 
presence of drug resistant minority variants. 
 
Deep sequencing has been utilised to detect mutations not only sooner than 
Sanger sequencing, but also in samples where Sanger sequencing had 
initially failed to detect mutations. (Sahoo et al., 2013, Chou et al., 2014). 
Sanger sequencing, however, has the advantage of being less prone to 
artificial mutagenesis than next generation sequencing (Capobianchi et al., 
2013, Barzon et al., 2013, Gargis et al., 2016). 
 
The UL54 DNA polymerase region was not analysed. UL54 mutations 
characteristically evolve after UL97 mutations. Detection of UL54 mutations 
in the absence of UL97 mutations, although rare, may be associated with 
resistance to ganciclovir. (Green et al., 2016). Presence of UL54 mutations is 
associated with high level of resistance to ganciclovir, foscarnet and 
cidofovir. Their presence should be assessed where treatment with foscarnet 
and cidofovir is considered. 
 
Unusual patterns of CMV drug resistance mutation emergence have been 
described. Iwasenko et al (2007) describe a fascinating case of the 
emergence of a foscarnet-resistant / ganciclovir-sensitive UL54 drug 
resistance mutation (T700A) one year after the disappearance of a UL97 
ganciclovir resistant mutation (L595S). The detection of the T700A UL54 
mutation occurred in the absence of concurrent foscarnet use, under 
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ganciclovir selective pressure in a bone marrow recipient with X-linked 
severe combined immunodeficiency. 
 
This case report further highlights the influence of quasispecies, sampling 
bias in relation to sample type and compartmentalisation, and the influence of 
underlying host factors in detection and interpretation of CMV drug resistance 
mutations (Iwasenko et al., 2007). 
3.6.4 Bias 
 
Research bias can be briefly defined as any systematic error introduced into 
sampling or testing by selecting or encouraging one outcome or answer over 
others. 
 
Bias can arise from the study design, population selection, sampling and data 
analysis, causing interference with the interpretation and significance of study 
findings. The nature of PCR, PCR reaction conditions and sequencing 
reactions are additional sources of bias and these are discussed briefly in 
this section. 
 




The study was designed to detect CMV UL97 drug resistance mutations in 
the retrospective patient group and the clinician referred group of patients 
with serially elevated viral loads who may be at risk for presence of CMV 
drug resistance mutations, as well as those with documented exposure to 
ganciclovir who prospectively did not suppress their CMV viral loads. 
 
Findings of this study should be interpreted in this context, which may 
overinflate the magnitude of the problem of CMV drug resistance mutations 
in the source population. This selection bias is inherent of this particular 
study design, as risk of developing mutations cannot be measured without 
knowledge of CMV viral load levels, knowledge of risk groups and exposure 
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to ganciclovir or valganciclovir. Clinical interpretation of data and 
administration of ganciclovir are essential prerequisities towards assessment 
of outcomes. 
 
Due to the limited resources available for this study as well as the fact that it 
was largely a proof-of-concept study we had limited control over this 
selection bias, to be able to detect CMV UL97 drug resistance mutations 
exposure to ganciclovir is a prerequisite (Gerhard, 2008, Pannucci and 
Wilkins, 2010). 
 
There was no knowledge by the investigators of prior ganciclovir use, 
duration or dosage in the retrospective patient category. Exposure to 
ganciclovir was assumed based on serial screening of CMV viral load values, 
current local practices of ganciclovir initiation above recommended threshold 
and diagnoses provided on the laboratory request form. This may 
underestimate the prevalence of CMV UL97 mutations. The prospective 
category of patients in whom mutations were detected was largely paediatric 
patients. In this group, there was a higher level of willingness by the 
paediatricians to refer patients for drug resistance testing. 
 
This may skew the association of incidence of CMV UL97 mutations towards 
a higher magnitude than that which exists in this sample population. 
 
PCR Amplification, Sequencing and Sequence Analysis Bias 
 
Acinas et al (2005) distinguishes PCR artefacts in laboratory studies into two 
categories, namely those related to sequence artefacts (PCR errors i.e. 
formation of chimeric molecules, formation of heteroduplexes and Taq DNA 
polymerase errors) and those resulting in an abnormal distribution of PCR 
products as a result of unequal PCR amplification (PCR bias) (Acinas et al., 
2005). 
 
Wagner et al (1994) and Bracho et al (2004) further characterise these 
effects to occur because of PCR selection and drift. They describe PCR 
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selection to occur because of mechanisms such as preferential denaturing 
due to guanine-cytosine (GC) content in the primer and template, differential 
efficiency of primer hybridisation or differential DNA polymerase extension 
rates because of secondary structures of DNA. This may lead to preferential 
amplification of certain templates resulting in their overrepresentation in the 
final PCR mixture. They further attribute PCR drift as being related to random 
variation in the early cycles of the reaction which is not repeatable in 
subsequent PCR amplification experiments of the same gene family (Wagner 
et al., 1994, Bracho et al., 2004). 
 
Although these publications referred to amplification of the 16sRNA gene, the 
concept is well described in virological studies. Yao et al (2005) described 
three major sources of sequencing error in their work on amplification of the 
Hepatitis C virus (HCV) Genotype 1 open reading frame –a highly 
genotypically variable virus. These included, sequencing errors, enzymatic 
errors during reverse transcription PCR (RT-PCR) and primer bias during 
PCR (Yao and Tavis, 2005). Reverse transcription, a prerequisite step in the 
amplification of RNA viruses to generate complementary DNA (cDNA), may 
also contribute towards the formation of primer-dimers or truncated products 
that can interfere with sequencing. This paper additionally highlights the 
importance of careful primer design, particularly for genetically 
heterogeneous templates, direct sequencing of the amplicons, adequate 
sequencing depth and bidirectional sequencing to reduce the bias. 
 
PCR amplification cycles, primer annealing temperatures and amplification of 
multiple templates from a single reaction are additional factors that can affect 
PCR reaction amplification bias (Suzuki and Giovannoni, 1996, Polz and 
Cavanaugh, 1998, Sipos et al., 2007). 
 
Thermus aquaticus polymerase (Taq polymerase) is a thermostable DNA 
polymerase enzyme used in PCR reactions to amplify DNA. Enzymatic errors 
in sequencing, particularly for RNA viruses, have been documented to be 
approximately 0.2-2 x10-4 errors per base pair per cycle (Eckert and Kunkel, 
1990, Smith et al., 1997a, Bracho et al., 1998). 
50 
 
Tindall and Kunkel (1988) simplify these Taq Polymerase error rates as 1 
nucleotide substitution in every 9000 bases polymerised and 1 frameshift 
error in every 41 000 bases polymerized (Tindall and Kunkel, 1988). Eckert 
and Kunkel (1990) suggest that despite these Taq polymerase error rates, 
within a well -defined PCR reaction (adequate pH, dNTP and MgCl2 
concentrations), Taq polymerase can still generate highly accurate DNA 
synthesis (Eckert and Kunkel, 1990). A high fidelity DNA polymerase, which 
has a hundred times lower error rates than Taq polymerase, is preferred for 
experiments requiring cloning, amplification of large fragments above 1000 
base pairs and next generation sequencing. 
 
Smith et al (1997) further suggest that avoiding analysis of cloned sequences 
and sequencing directly from PCR products derived by amplification of a 
single target region is beneficial in reducing these sources of error, a finding 
supported by Simmonds et al (1990) in their work on amplification of the HIV 
provirus (Simmonds et al., 1990, Smith et al., 1997a). 
 
Within the context of the aforementioned factors, we amplified a single region 
of the CMV genome, targeting a gene not responsible for genotypic variation. 
CMV genotyping requires amplification of glycoprotein B (UL55), glycoprotein 
N (UL73) or glycoprotein H (UL75) (Chou, 1992, Tarrago et al., 2003, 
Pignatelli et al., 2003, Mujtaba et al., 2016). 
 
Bidirectional sequencing was performed directly from the PCR products 
without prior cloning. Two independent observers to confirm sequence 
findings performed the sequence analysis. 
 
The theoretical bias of database analysis against available published 
sequences is a factor outside of our control. Databases (such as the NCBI 
BLAST and University of Ulm Mutation Resistance Analyzer, which were 
used in this study, tend to publish sequences based on findings pertaining to 
particular geographical locations or pathogens of interest at particular 
timepoints, which may bias findings. 
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The University of Ulm database is the only freely available online tool for the 
analysis of CMV drug resistance mutations. The NCBI BLAST database, 
although limited by geographical bias towards sequences from first world 
countries (mainly Britain and America), provides all currently published 
sequences from groups working on CMV and hence provides the best 
benchmark of our findings. This bias is predominantly a reflection of limited 
work done in this arena from developing countries. 
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Chapter 4.Conclusion and Recommendations 
 
In conclusion, these findings demonstrate that CMV UL97 mutations occur in 
the local solid organ, stem cell transplant population and patients with 
primary immunodeficiencies following prolonged treatment with ganciclovir. 
Not only were sequence variants detected, but also significant drug 
resistance mutations conferring varying levels of resistance to ganciclovir. 
This is the first study of this nature in South Africa that attempts to describe 
the existence and nature of CMV UL97 drug resistance mutations. 
 
The findings of this study demonstrate a higher prevalence of CMV UL97 
drug resistance mutations (20%) compared to that described in international 
literature (0-10%). The prevalence of CMV UL97 mutations in the 
retrospective group was 5/33 (15%) and 3/8 (38%) in the clinician referred 
group of patients with elevated CMV viral load on ganciclovir. 
 
There were no CMV UL97 mutations detected in the HIV-infected patients we 
tested. This may be a reflection on shorter duration of treatment in these 
patients, which is usually for six weeks according to current local practice. 
 
The haematological oncology patient category displayed the presence of 
clinically non-significant CMV UL97 sequence polymorphisms, which do not 
affect response to antiviral treatment, hence should not be reported to 
clinicians. 
 
Our findings suggest that patients with primary immunodeficiency disorders 
or post stem-cell transplantation were at a higher risk of developing CMV 
UL97 mutations. Transplant recipients who undergo extensive myelo-ablation 
and immunosuppression, in particular, are at the most increased risk of 
developing drug resistance mutations. These findings should be interpreted 
within the context of the study design, sample size and limited referral of 
adult patients in the prospective category for drug resistance testing. 
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The introduction of CMV genotypic resistance testing provided important 
insight into the development of ganciclovir mutations in special at-risk 
populations. Among our cases, we found the use of acyclovir prophylaxis 
might play a role in the evolution of mutations, as both Patient F and Patient 
G (Table 3) were adult stem cell transplant recipients who were on acyclovir 
prophylaxis at the time of UL97 genotypic testing. 
 
Presence of viral quasispecies, underlying host factors promoting CMV 
replication, drug exposure history, compartment sampled and sequencing 
platform need to be considered when interpreting results. Testing at a 
singular timepoint may fail to detect CMV UL97 drug resistance mutations. 
 
These findings suggest a need for the detailed assessment of the presence 
of CMV UL97 drug resistance mutations in clinically relevant settings. 
Accurate documentation of ganciclovir dosage, duration, host factors 
favouring CMV replication and clinical outcomes should be undertaken. The 
potential role of acyclovir exposure preceding ganciclovir use requires further 
exploration. 
 
Genotypic testing in appropriate clinical scenarios stands to provide early 
detection of drug resistant mutations, eliminate the need for ongoing 
inadequate treatment with ganciclovir, reduction of ganciclovir associated 
adverse events and alert clinicians towards adequate tailoring of therapy 
such as reduction of immunosuppressants. Most importantly, assessment for 
CMV drug resistant mutations would provide essential baseline data towards 
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BACKGROUND 
Cytomegalovirus (CMV) drug resistance mutations through widespread use 
of ganciclovir have been widely reported in international literature, particularly 
in the post- transplant setting. However, a genotypic assay to detect CMV 
drug resistance is not available in South Africa and the prevalence of these 
mutations is therefore unknown. 
OBJECTIVES/AIMS 
We aimed to set up and evaluate an assay to detect CMV UL 97 mutations 
by analysing External Quality Assurance (EQA) panel and patients referred 
by clinicians with possible ganciclovir resistance. 
METHODS 
A literature search was conducted to obtain published primers and a nested 
Polymerase Chain Reaction protocol for a 707bp region of the UL97 gene for 
sequencing. Three whole blood samples from patients with a clinical history 
suggestive of ganciclovir resistance as well as 5 EQA samples from Quality 
Control for Molecular Diagnostics panel were tested in the evaluation. 
RESULTS: 
UL97 mutations were identified in 5/5 (100%) EQA samples. Six different 
UL97 mutations (100%): A594V, H520Q, L595S, M460V, C603W, G598S 
and a polymorphism associated with hyper susceptibility to ganciclovir 
(D605E) were detected. The G598S mutation (a vaccinia virus recombinant) 
was present in all EQA samples. 
The L 595S mutation was identified in a 3-year-old child with myelodysplasia 
post –haematopoetic stem cell transplant who had persistently elevated CMV 
Viral Load despite being on ganciclovir. However, despite the presence of the 





Ganciclovir is used on a large scale in transplant settings. This preliminary 
work has shown that resistance mutations to ganciclovir may be more 
prevalent than initially suspected. It has also highlighted the need for 
documenting the prevalence, nature and effect on clinical outcomes of 
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BACKGROUND 
Ganciclovir Cytomegalovirus (CMV) drug resistance mutations (DRM) have 
been widely reported in international literature, particularly in the post-
transplant setting. However; without access to genotyping assays; the 
prevalence of these mutations is unknown in South Africa. We aimed to set 
up an in-house assay to document the prevalence of CMV UL97 DRM 
amongst immune-suppressed populations in Cape Town. 
METHODS 
A literature search was conducted to obtain published primers and a nested 
Polymerase Chain Reaction protocol for a 707bp region of the UL97 gene for 
sequencing. A Quality Control for Molecular Diagnostics (QCMD) CMV DRM 
panel was used for validation.  Subsequently, a further 37 samples from 
transplant, haematological oncology, HIV- infected and clinician-referred 
patients with possible ganciclovir resistance were evaluated. 
RESULTS: 
6/6 UL97 mutations were correctly identified in 5/5(100%) QCMD samples, 
3/30 (10%) of transplant/haematological oncology and 2/7 (28.57%) of 
clinician-referred patients. Five mutations from 5/37(13.52%) individuals were 
identified, namely L595S, H520Q, C592G, M460V and D605E. Noteworthy, 
the H520Q mutation was detected in a 2-year-old child with pre-B Acute 
Lymphocytic Leukemia who demised. However, despite the presence of 
L595S mutation another 3-year-old child with myelodysplasia post-stem cell 




CMV DRM to ganciclovir may be more prevalent than initially suspected. The 
prevalence and clinical outcomes of these mutations needs to be better 
documented. 
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